Fundraise / allotmentFiled on BSE ·
Venus Pipes & Tubes approved preferential issue of 22.27 lakh shares at ₹1670 each
Venus Pipes · Industrial Products
What the filing says
- Board approved preferential issue of 22,27,544 equity shares at ₹1670 per share totaling ₹372 crore
- Shareholders' EGM scheduled on 08 October 2026 for approval; cut-off date for voting is 01 October 2026
- Post-issue promoter shareholding will be 43.71%; public shareholding will increase to 56.29%
Original filing
Announcement under Regulation 30 (LODR)-Issue of Securities
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue: Rank 1Margin: Rank 1
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Venus Pipes
- Board / shareholder meeting outcomeVenus Pipes & Tubes issues corrigendum to EGM Notice for preferential issue clarifications
- Fundraise / allotmentVenus Pipes & Tubes Limited approves preferential issue of 22.27 lakh shares
- Fundraise / allotmentVenus Pipes & Tubes Ltd approves preferential issue of 22.27 lakh shares worth ₹372 crore
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentACS Technologies LtdACS Technologies Limited receives in-principle approval for preferential issue of shares
- Fundraise / allotmentGuj. Themis Bio.Gujarat Themis Biosyn Limited announces dividend, fund raise, and AOA amendment
- Fundraise / allotmentGravita India LtdGravita India Ltd announces Rs. 94.81 crore rights issue by subsidiary RMIL
- Fundraise / allotmentClean Max EnviroClean Max Enviro Energy lists ₹2,500 crore green non-convertible debentures on BSE
- Fundraise / allotmentCube HighwaysCube Highways Fund Advisors Pvt Ltd schedules Board meeting on Oct 6, 2026 for fund raising approval
- Fundraise / allotmentCube HighwaysCube Highways Trust allots ₹1,150 crore senior secured NCDs at 7.5% coupon
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.